The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

Cancer

Volumn 106, Issue 1, 2006, Pages 112-119

  Kuendgen, Andrea ^a   Schmid, Mathias ^b   Schlenk, Richard ^b   Knipp, Sabine ^a   Hildebrandt, Barbara ^a   Steidl, Christian ^c   Germing, Ulrich ^a   Haas, Rainer ^a   Dohner, Hartmut ^b   Gattermann, Norbert ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Acute myeloid leukemia; Histone deacetylase inhibitors; Valproic acid

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; RETINOIC ACID; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CELL DIFFERENTIATION; CLINICAL TRIAL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PLEURA EFFUSION; PRIORITY JOURNAL; QUALITY OF LIFE; SKIN TOXICITY; THROMBOCYTOPENIA; TREMOR;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRETINOIN; VALPROIC ACID;

EID: 29744454120     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21552     Document Type: Article

References (43)

1. Martin ML, Regan CM. The anticonvulsant valproate teratogen restricts the glial cell cycle at a defined point in the mid-G1 phase. Brain Res. 1991;554:223-228.
2. Bacon CL, Gallagher HC, Haughey JC, Regan CM. Antiproliferative action of valproate is associated with aberrant expression and nuclear translocation of cyclin D3 during the C6 glioma G1 phase. J Neurochem. 2002;83:12-19.
3. Cinatl J Jr, Cinatl J, Driever PH, Kotchetkov R, Pouckova P, Kornhuber B, Schwabe D. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs. 1996:7:766-773.
4. Werling U, Siehler S, Litfin M, Nau H, Gottlicher M. Induction of differentiation in F9 cells and activation of peroxisome proliferator-activated receptor delta by valproic acid and its teratogenic derivatives. Mol Pharmacol. 2001;59:1269-1276.
5. Lampen A, Carlberg C, Nau H. Peroxisome proliferator-activated receptor delta is a specific sensor for teratogenic valproic acid derivatives. Eur J Pharmacol. 2001;431:25-33.
6. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20:6969-6978.
7. Walmod PS, Skladchikova G, Kawa A, Berezin V, Bock E. Antiepileptic teratogen valproic acid (VPA) modulates organisation and dynamics of the actin cytoskeleton. Cell Motil Cytoskeleton. 1999;42:241-255.
8. Walmod PS, Foley A, Berezin A, Ellerbeck U, Nau H, Bock E, Berezin V. Cell motility is inhibited by the antiepileptic compound, valproic acid and its teratogenic analogues. Cell Motil Cytoskeleton. 1998;40:220-237.
9. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA, et al. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol. 2004;65:520-527.
10. Zgouras D, Becker U, Loitsch S, Stein J. Modulation of angiogenesis-related protein synthesis by valproic acid. Biochem Biophys Res Commun. 2004;316:693-697.
11. Phiel CJ, Zhang F, Huang EY, et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276:36734-36741.
12. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res. 2004;64:1079-1086.
13. Kramer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA, et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 2003;22:3411-3420.
14. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92:1210-1216.
15. Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 2002;13:1-13.
16. Melnick A, Licht JD. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol. 2002;9:322-332.
17. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042-2054.
18. Wang J, Saunthararajah Y, Redner RL, Liu JM. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res. 1999;59:2766-2769.
19. Redner RL, Wang J, Liu JM. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood. 1999;94:417-428.
20. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol. 1998;18:7185-7191.
21. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 2001;61:2-7.
22. Kawagoe R, Kawagoe H, Sano K. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and-independent apoptotic signaling pathways. Leuk Res. 2002;26:495-502.
23. Tang R, Faussat AM, Majdak P, Perrot JY, Chaoui D, Legrand O, Marie JP. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia. 2004;18:1246-1251.
24. Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood. 2004;104:1266-1269.
25. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 1999;10:1419-1432.
26. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
27. Cheson BD, Bennett JM, Bloomfield CD. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-4649.
28. Erratum in: J Clin Oncol. 2004;22:576.
29. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671-3674.
30. Guel H, Wassermann B, Romanski A, et al. Effect of the histone deacetylase inhibitor valproic acid in combination with all-trans retinoic acid on normal and malignant hematopoesis [abstract]. Blood. 2003;102:2313.
31. Nervi C, Lo Coco F, Pelicci PG. Valproic acid plus retinoic acid induce differentiation in chemotherapy resistant acute myeloid leucemia patients [abstract]. Blood. 2004;104:
32. Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ, et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res. 2001;7:2330-2339.
33. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, et al. A phase I and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005;105:959-967.
34. Gojo I, Gore SD, Jiemjiet A. Phase I study of histone deacetylase inhibitor MS-275 in adults with refractory or relapsed myeloid malignancies [abstract]. Blood. 2003;102:1408.
35. Garcia-Manero G, Canalli AA, Wierda W, et al. Phase I study of oral suberoylanilide hydroxamic acid (SAHA) in patients with advanced leukemias or myelodysplastic syndromes [abstract]. Blood. 2003;102:4742.
36. Olatoyosi MO, Alkan S, Stock W. The histone deacetylase inhibitor depsipeptide has differential activity in specific cytogenetic subsets of acute myeloid leukaemia (AML) [abstract]. Blood. 2004;102:
37. Gozzini A, Rovida E, Dello Sbarba P, Galimberti S, Santini V. Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts. Cancer Res. 2003;63:8955-8961.
38. Huang S, Brandt SJ. mSin3A regulates murine erythroleukemia cell differentiation through association with the TAL1 (or SCL) transcription factor. Mol Cell Biol. 2000;20:2248-2259.
39. Watamoto K, Towatari M, Ozawa Y, Miyata Y, Okamoto M, Abe A, et al. Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation. Oncogene. 2003;22:9176-9184.
40. Schlenk RF, Frohling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F, et al. AML Study Group Ulm. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia. 2004;18:1798-1803.
41. Pallis M, Turzanski J, Higashi Y, Russell N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma. 2002;43:1221-1228.
42. Burgess A, Ruefli A, Beamish H, Warrener R, Saunders N, Johnstone R, Gabrielli B. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene. 2004;23:6693-6701.
43. Garcia-Manero G, Kantarjian H, Issa JP. Results of a phase I/II study of the combination of 5-aza-2′-deoxycytidine (DAC) and valproic acid (VPA) in patients with leukaemia [abstract]. Blood. 2004;104:263.